US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
biotech · Bile acid diarrhoea · Transthyretin cardiac amyloidosis · GLUE
Monte Rosa Therapeutics
Monte Rosa Therapeutics drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Boston, USA HQ
213 Employees
Public company Type
GLUE · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boston, USA
- Employees
- 213
- Programs
- 7
- Drugs
- 14
- Patents
- 72
Monte Rosa Therapeutics pipeline
Portfolio lens on 14 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Monte Rosa Therapeutics drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Dopamine D2 receptor agonist
-
Development asset linked to Monte Rosa Therapeutics in public FDA and regional records.
-
Development asset linked to Monte Rosa Therapeutics in public FDA and regional records.
-
colesevelam
Cardiovascular system (C10)Cardiovascular system (C10) compound in Monte Rosa Therapeutics's portfolio.
-
Development asset linked to Monte Rosa Therapeutics in public FDA and regional records.
-
Development asset linked to Monte Rosa Therapeutics in public FDA and regional records.
-
Development asset linked to Monte Rosa Therapeutics in public FDA and regional records.
-
Development asset linked to Monte Rosa Therapeutics in public FDA and regional records.
-
Development asset linked to Monte Rosa Therapeutics in public FDA and regional records.
-
Development asset linked to Monte Rosa Therapeutics in public FDA and regional records.
-
Development asset linked to Monte Rosa Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Transthyretin.
- Target
- Transthyretin
- Mechanism
- Transthyretin stabiliser
-
temozolomide
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor